+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dong-A Socio Holdings Co Ltd (000640) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 38 Pages
  • August 2023
  • GlobalData
  • ID: 1367832
Dong-A Socio Holdings Co Ltd (000640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd, a subsidiary of Dong-A Socio Group that offers business management services. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group focuses on new business investments, APIs, OTC products, consumer goods, prescription drugs, development of biomedicines, and research and development of new innovative drugs. Its major products include quasi-drug, Bacchus; a cold medicine, Anti-inflammatory, Antipyretic, Analgesic Drug, namely, Panpyrin-T, Panpyrin Q; Morning Care; a tampon; contraceptive medicine such as Myvlar; among others. Dong-A Socio Holdings is headquartered in Seoul, South Korea.

Dong-A Socio Holdings Co Ltd Key Recent Developments

  • May 03, 2022: Donga Socio Holdings Prior Notice on Disclosure of Final Earnings

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Dong-A Socio Holdings Co Ltd - Key Facts
  • Dong-A Socio Holdings Co Ltd - Key Employees
  • Dong-A Socio Holdings Co Ltd - Major Products and Services
  • Dong-A Socio Holdings Co Ltd - History
  • Dong-A Socio Holdings Co Ltd - Company Statement
  • Dong-A Socio Holdings Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Dong-A Socio Holdings Co Ltd - Business Description
  • Dong-A Socio Holdings Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Dong-A Socio Holdings Co Ltd - Strengths
  • Dong-A Socio Holdings Co Ltd - Weaknesses
  • Dong-A Socio Holdings Co Ltd - Opportunities
  • Dong-A Socio Holdings Co Ltd - Threats
  • Dong-A Socio Holdings Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Dong-A Socio Holdings Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 03, 2022: Donga Socio Holdings Prior Notice on Disclosure of Final Earnings
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Dong-A Socio Holdings Co Ltd, Key Facts
  • Dong-A Socio Holdings Co Ltd, Key Employees
  • Dong-A Socio Holdings Co Ltd, Major Products and Services
  • Dong-A Socio Holdings Co Ltd, History
  • Dong-A Socio Holdings Co Ltd, Subsidiaries
  • Dong-A Socio Holdings Co Ltd, Affiliate
  • Dong-A Socio Holdings Co Ltd, Joint Venture
  • Dong-A Socio Holdings Co Ltd, Key Competitors
  • Dong-A Socio Holdings Co Ltd, Ratios based on current share price
  • Dong-A Socio Holdings Co Ltd, Annual Ratios
  • Dong-A Socio Holdings Co Ltd, Interim Ratios
  • Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Dong-A Socio Holdings Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Dong-A Socio Holdings Co Ltd, Performance Chart (2018 - 2022)
  • Dong-A Socio Holdings Co Ltd, Ratio Charts
  • Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Meiji Seika Pharma Co Ltd
  • PharmaResearch Bio Co Ltd
  • Bayer Yakuhin Ltd
  • Asahi Kasei Pharma Corp
  • Oscotec Inc
  • Daewoong Bio Inc
  • SeouLin Bioscience Co Ltd
  • Daewoong Bio Inc
  • SeouLin Bioscience Co Ltd
  • PharmaResearch Bio Co Ltd
  • Bayer Yakuhin Ltd
  • Asahi Kasei Pharma Corp
  • Oscotec Inc
  • Meiji Seika Pharma Co Ltd